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ABSTRACT
Objective: Traditional cost–utility analysis assumes that
all beneﬁts from health-related interventions are captured
by the quality-adjusted life-years (QALYs) gained by the
few individuals whose outcome is improved by the inter-
vention. However, it is possible that many individuals
who do not directly beneﬁt from an intervention receive
utility, and therefore QALYs, because of the passive ben-
eﬁt (aka sense of security) provided by the existence of
the intervention. The objective of this study was to eval-
uate the impact that varying quantities of passive beneﬁt
have on the cost-effectiveness of airline deﬁbrillator
programs.
Methods: A decision analytic model with Markov proc-
esses was constructed to evaluate the cost-effectiveness of
deﬁbrillator deployment on domestic commercial passen-
ger aircraft over 1 year. Airline passengers were assigned
small incremental utility gains (.001–.01) during an esti-
mated 3-hour ﬂight to evaluate the impact of passive ben-
eﬁt on overall cost-effectiveness.
Results: In the base case analysis with no allowance for
passive beneﬁt, the cost-effectiveness of airline automated
external deﬁbrillator deployment was $34,000 per QALY
gained. If 1% of all passengers received utility gain of
.01, the cost-effectiveness declined to $30,000. Cost-
effectiveness was enhanced when the quantity of passive
beneﬁt was raised or the percentage of individuals receiv-
ing passive beneﬁt increased.
Conclusions: Automated external deﬁbrillator deploy-
ment on passenger aircraft is likely to be cost-effective. If
a small percentage of airline passengers receive incremen-
tal utility gains from passive beneﬁt of automated exter-
nal deﬁbrillator availability, the impact on overall cost-
effectiveness may be substantial. Further research should
attempt to clarify the magnitude and percentage of
patients who receive passive beneﬁt.
Keywords: automated external deﬁbrillator, cardiac
arrest, cost-effectiveness, passive beneﬁt, public access
deﬁbrillation.
Introduction
In 1993 the US Public Health Service convened The
Panel on Cost-Effectiveness in Health and Medicine
to standardize the methodology and reporting of
cost-effectiveness studies. Among The Panel’s
principal recommendations was that all cost-
effectiveness analyses report results based on a soci-
etal perspective [1–3]. The rationale for this
approach had many factors, but was largely
dependent upon the panel’s judgment that the soci-
etal perspective best captured the total costs and
total beneﬁts of most health interventions.
According to The Panel [1], by taking the societal
perspective, “the analyst considers everyone
affected by the intervention, and all health effects
and costs that ﬂow from it are counted, regardless
of who would experience them.” Conducting a
cost-effectiveness analysis using the societal per-
spective generally requires that the researcher
include numerous categories of cost in the model
including costs of future medical care, costs related
to transportation, and costs related to family care-
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giving [4–7]. Likewise, the societal perspective sug-
gests that all relevant beneﬁts, both direct and
indirect, should be included in the analysis and are
reported in terms of quality-adjusted life-years
gained (QALYs). While the precise method of quan-
tifying these beneﬁts may vary (standard gamble,
time trade-off, etc.), all techniques for measurement
of these beneﬁts are similar in that the entire beneﬁt
of the intervention is assumed to have been cap-
tured in the QALYs gained by the few individuals
who receive the speciﬁc intervention [8,9]. There is
no allowance for gains in utility that may accrue
among individuals who never require the interven-
tion, but instead receive passive beneﬁt. Further-
more, traditional cost-effectiveness analysis makes
no allowance for the potential utility gains that
“innocent bystanders” may receive when an inter-
vention is used to assist somebody else. Passive ben-
eﬁt may be construed as a valuation of the “sense of
security” certain individuals may receive because of
the availability or use of a particular health inter-
vention, even if the speciﬁc individuals never per-
sonally require the use of the intervention. Cost–
utility models that assume a truly societal perspec-
tive accounting for all costs and all beneﬁts resulting
from an intervention should attempt to account for
this passive beneﬁt.
The recently published study by Page et al. [10]
demonstrating that deployment of automated
external deﬁbrillators (AEDs) on passenger aircraft
may increase the survival rates for cardiac arrest
victims provides the opportunity to assess the
potential impact of passive beneﬁt on overall cost-
effectiveness. Airline deﬁbrillator deployment offers
an important opportunity to study the impact of pas-
sive beneﬁt because, while only approximately 240
in-ﬂight cardiac arrests occur annually in the United
States,  over  440  million  passengers  ﬂy  on  domes-
tic airlines annually and therefore are indirectly
exposed to AEDs. If only a small fraction of these
passengers receive a modest quantity of passive ben-
eﬁt from AED availability, the impact could be sub-
stantial. Therefore, we created a decision analytic
model to measure the clinical and economic costs
and beneﬁts associated with deployment of AEDs on
passenger aircraft. We then attempted to estimate the
impact of various levels of passive beneﬁt on the
overall cost-effectiveness of AED deployment.
Methods
Literature Review
Using Medline, the 1966 to 2002 medical literature
was searched using the keywords cardiac arrests,
deﬁbrillators, and airline medical events. Model
inputs were based on this literature as well as hand
searching of relevant journals and contact with
established experts in aviation medicine.
Decision Analytic Model
We constructed a decision analytic model (Fig. 1)
with Markov processes to estimate the clinical and
economic consequences of two management strate-
gies in a cohort of typical airline passengers ﬂying
on commercial US aircraft carrying an average of
110 passengers per ﬂight during a 1-year period
consisting of 4 million commercial passenger ﬂights:
1) strategy 1—passengers ﬂy on aircraft equipped
with standard, FAA-mandated medical kits; 2)
strategy 2—passengers ﬂy on aircraft equipped with
standard medical kits supplemented by commer-
cially available AED.
We performed the analysis using decision-ana-
lytic software (DATA 4.0, Treeage, Wiliamstown,
MA). The only difference between the two strate-
gies was the availability of AEDs to the passengers
in Strategy 2. Clinical outcomes assessed for each
strategy included total survivors of cardiac arrest,
life-years gained, and QALYs. All historical costs
were adjusted for inﬂation at 3% per year. Likewise,
future costs and beneﬁts were discounted at 3% per
annum in accordance with the recommendations of
the Panel on Cost-Effectiveness in Health and Med-
icine [11].
Probability of Clinical Events
The probabilities and ranges of clinical events used
in the decision model are shown in Table 1. The
baseline probability of a medical event occurring on
a speciﬁc ﬂight was derived from several recent
studies and was estimated to be 1 event per 2500
ﬂights (.0004 events per ﬂight) [10,12,13]. Data
from these same studies demonstrated that approx-
Figure 1 Decision model: Model for strategies 1 and  and 2 are
identical except for the availability of AEDs and  and resulting changes













































































imately 15% of these medical events were actually
cardiac arrests [10,12,13].
Strategy 1—no AED on aircraft. For airline
passengers who suffer cardiac arrests, all are
treated with CPR alone since AEDs are not availa-
ble. There are no studies speciﬁcally reporting the
probability of survival after cardiac arrest on pas-
senger aircraft in the absence of AEDs. However,
investigations have revealed that a minimum of
20 minutes is required before passengers suffering
medical emergencies on aircraft can be evacuated to
receive advanced medical care [14]. Therefore, it is
reasonable to assume that survival of these patients
would approximate survival rates of cardiac arrest
victims in other venues with similarly long delays
before care is initiated. Data suggest that under
these conditions, approximately 6% of cardiac
arrest victims would survive to hospital admission
[15–17]. Only an estimated 30% of patients who
survive to hospital admission (2% of all arrest vic-
tims) would be expected to survive to hospital dis-
charge [15–18].
Strategy 2—AED used for all medical events.
Under this strategy all passengers suffering medical
events receive monitoring with the AED. As in strat-
egy 1, 15% of medical events are cardiac arrests.
Based on the results of the studies by Page and
O’Rourke [10,13], an estimated 36% of cardiac
arrest victims can be expected to survive to hospital
admission. Of those patients who are successfully
resuscitated, approximately 46% (17% of all
cardiac arrest victims) will survive to hospital
discharge.
Costs
The cost estimates used in the model are shown in
Table 1. The cost of an AED was estimated at
$2500 with a useful life of 5 years [19]. Accessing
and unpacking the AED results in a $150 restocking
charge, regardless of whether a shock is adminis-
tered [19]. AED training costs were not included in
the model because one recent report suggested that
the incremental costs of AED training are negligible,
while others have suggested that AED training may
actually be unnecessary [20–22].
The estimated costs of hospitalization for cardiac
arrest survivors have been published in several stud-
ies and range from $30,000 to $200,000 [23,24].
Larsen et al. [25] calculated costs of initial hospi-
talization of either $24,000 or $46,000 depending
on whether the patients received implantable car-
diac deﬁbrillators or not. We estimated a base case
cost of $46,000 by taking the average of the two
costs reported by Larsen et al. and adjusting for
inﬂation.
Survivors of cardiac arrests can be expected to
accrue substantial medical costs over their remain-
ing lifetime as a result of their cardiac disease. A
recent study by Groeneveld et al. [26] reported
annual medical costs of cardiac arrest survivors of
$10,000 during the ﬁrst year and $7400 in subse-
quent years.




Probability of medical event on given ﬂight .0004 .0002–.0013 [10,12,13]
Probability that medical event is arrest .15 .05–.25 [10,12,13]
Probability of successful resuscitation with AED .36 .20–.40 [10,12,13]
Probability of successful resuscitation without AED .06 .02–.10 [15–17]
Probability of survival to hospital discharge with AED .46 .35–.55 [10,13]
Probability of survival to hospital discharge without AED .30 .10–.50 [15–18]
Probability of surviving arrest unimpaired .89 .80–1 [30]
Probability of surviving arrest mildly impaired .09 0–.15 [30]
Probability of surviving arrest severely impaired .02 0–.05 [30]
Costs ($)
AED hardware cost (each) 2,500 1,500–3,000 [19]
AED supplies (per use) 150 100–200 [19]
Hospitalization for in-hospital death 3,700 2,650–5,300 [26]
Hospitalization for arrest survivor 46,000 30,000–200,000 [23,25]
Future medical costs for arrest survivor
First year [26] 10,000 9,300–13,300 [38]
Subsequent years [38] 7,400 5,800–10,600 [38]
Life expectancy
Mean life expectancy for arrest survivors (years) 6.0 4–8 [27–30]
Utility for arrest survivors (0–1 scale)
Unimpaired 0.78 0.5–1 [31]
Mildly impaired 0.07 0–.4 [32]
Severely impaired 0 0–.25 [32]
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Life Gained from AED
The beneﬁt of AED deployment stems from any
increase in life expectancy among passengers
assigned to strategy 2 when compared with those in
strategy 1. Mean life expectancies for cardiac arrest
survivors in both strategy 1 and strategy 2 were cal-
culated based on data from several studies of long-
term survival after cardiac arrest [27–30]. Using
these estimates, expected survival after cardiac
arrest was estimated to be 6 years.
Quality-of-Life Adjustment
Patients surviving cardiac arrest may have varying
degrees of neurologic impairment. The probabilities
of various degrees of impairment were based on
data from Cobbe et al. [30–32], and utilities were
then discounted appropriately.
Passive Beneﬁt
The precise value that airline passengers assign to
the passive beneﬁt of AED availability is currently
unknown. It is, however, possible to make some rea-
sonable estimates about the percentage of airline
passengers who might receive some utility gain from
passive beneﬁt of AED availability based on knowl-
edge of the prevalence of cardiovascular disease and
associated risk factors. For example, the American
Heart Association estimates that 20% of all Amer-
icans have cardiovascular disease; more speciﬁcally
5% of all Americans have coronary artery disease
[33,34]. Similarly, 7% of all Americans are esti-
mated to have diabetes [35].
Given the aging population and prevalence of
risk factors for coronary disease, in our base case
we estimated that 1% of the 440 million annual air-
line passengers received a utility gain of .01 during,
but not before or after, the estimated 3- hour ﬂight
(Table 3).
Sensitivity Analysis
Model inputs. Sensitivity analysis was performed
using two different techniques. First, one-way sen-
sitivity analysis was performed for each model input
across the entire range of values reported in the lit-
erature. We then performed two-way sensitivity
analyses for selected inputs that we identiﬁed as
critical in the one-way analyses.
Passive beneﬁt. Because of the substantial uncer-
tainty regarding both the percentage of airline pas-
sengers who may receive a passive beneﬁt and the
magnitude of this passive beneﬁt, sensitivity analy-
sis was conducted to assess how variations in these
variables would impact the overall cost-effective-
ness. The percentage of airline passengers receiving
passive beneﬁt was varied from 0.1% to 50% and
the utility gain was varied between .001 and .01.
Results
Clinical Outcomes
Based on an estimated 4 million annual commercial
passenger ﬂights by domestic carriers, deployment
of AEDs on all such ﬂights (strategy 2) could be
expected to save an incremental 35 lives annually
when compared with no AED (strategy 1) (Table 2).
When this survival beneﬁt is converted into quality-
adjusted life expectancy, strategy 2 results in an
annual net gain of 210 life-years and 149 QALYs
when compared with strategy 1.
Cost of AED Deployment
Based on an estimated 4 million annual ﬂights, fully
implementing AED programs across all commercial
aircraft would be expected to cost an incremental
$5.0 million annually: $1.3 million annually for the
AED, $240,000 for AED testing and repackaging
after each use, $100,000 for in-hospital deaths,
$1.6 million for hospitalization of the additional 35
cardiac arrest survivors, and $1.8 million for future
medical costs of arrest survivors.
Cost-Effectiveness: Base Case
In the base case analysis, strategy 2 offers improved
clinical outcomes (149 QALYs gained) at an
increased expense ($5.0 million) when compared
Table 2 Annual beneﬁt of AED deployment by strategy, based on an estimated 4 million domestic passenger ﬂights
Strategy 1—No AED Strategy 2—AED Strategy 2—Strategy 1
Medical events 1,600 1,600 —
Cardiac arrests  240 240 —
Survive to hospital discharge  5 40  35
Discounted life-years saved  30 240  210
QALY saved  21 170  149
Incremental cost of AED deployment ($) 5,000,000
Cost per QALY gained ($) 34,000
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with strategy 1. These results were used to calculate
an incremental cost-effectiveness of $34,000 per
QALY gained for strategy 2 when compared with
strategy 1.
Cost-Effectiveness: Base Case Including Passive Beneﬁt
Assuming that 1% of all passengers receive an
incremental utility gain of .01 during a 3-hour
ﬂight, the cost per QALY gained is reduced from
$34,000 to $30,000 (Table 3).
Cost-Effectiveness: Sensitivity Analysis
One-way sensitivity analysis. Given the uncer-
tainty in many of the model inputs, multiple one-
way sensitivity analyses were performed across the
ranges of data available for the model input varia-
bles (Table 4). Key variables that substantially
impact the results include the probability of cardiac
arrest, the relative effectiveness of the AED when
compared with CPR alone, the cost of hospitaliza-
tion for arrest survivors, and the mean life expect-
ancy of unimpaired cardiac arrest survivors.
Two-way sensitivity analysis. Figure 2 demon-
strates the impact of varying the probability of
in-air cardiac arrest (and thereby the number of
arrests) on the incremental cost-effectiveness of the
AED program. While the base-case medical event
rate (.0004 events per ﬂight) leads to an estimated
240 cardiac arrests annually, published data sug-
gests a range of 120 to as many as 780 annual
arrests may occur. Sensitivity analysis demonstrates
that the incremental cost per QALY gained associ-
ated with an expected 6-year mean life expectancy
for an arrest survivor may range from $68,000 (120
annual arrests) to $11,000 (780 annual arrests).
Passive Beneﬁt
Sensitivity analysis examining the relationship
between the number of passengers who receive a
passive beneﬁt and the magnitude of that passive
beneﬁt was also conducted. Table 3 demonstrates
that if 10% of all passengers receive a utility gain of
.01 during a 3-hour ﬂight, the QALY gain from pas-
sive beneﬁt may actually exceed the gain from the
direct beneﬁt of AED use. Figure 3 demonstrates the
relationship between overall cost-effectiveness of
AED deployment, the percentage of patients receiv-
ing passive beneﬁt, and the magnitude of the utility
gain they receive. Under base case assumptions, as
the percentage of passengers receiving an incremen-
tal .005 utility gain over a 3-hour ﬂight was
increased from 0.1% to 50%, the incremental cost-
effectiveness of AED deployment fell from $33,000
per QALY gained to $10,000. Alternatively, under













Annual number of airline passengers 440,000,000 440,000,000 440,000,000 440,000,000
Number receiving passive beneﬁt 0 440,000 2200,000 4,400,000
Utility beneﬁt 0 0.01 0.01 0.01
QALY gain from AED alone 149 149 149 149
QALY gain from passive beneﬁt 0 1.5 15 150
Total QALY gain from AED 149 150.5 187 299
Incremental cost of AED deployment ($) 5,000,000 5,000,000 5,000,000 5,000,000
Cost per QALY gain ($) 34,000 33,000 30,000 17,000
Table 4 Results from one-way sensitivity analysis across stated ranges
Variable Range Cost per QALY gained ($)
Probability of medical event (per ﬂight) .0002–.0013 79,000–12,000
Probability that medical event is cardiac arrest .05–.25 119,000–22,000
Probability of surviving arrest to discharge with AED .10–.30 74,000–21,000
AED purchase costs 1,500–3,000
($/ﬂight) .15–.30 35,000–39,000
Hospitalization for cardiac arrest survivors ($) 30,000–200,000 30,000–70,000
Future medical costs for arrest survivors ($) 41,000–71,000 37,000–45,000
Mean life expectancy for survivors 4–8 60,000–30,000
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base case assumptions, as the utility gain per pas-
senger was increased from .001 to .01 while holding
the percentage of passengers receiving this gain con-
stant at 5%, the cost per QALY gained for AED
deployment was reduced from $33,000 to $22,000.
Discussion
The recent report of airline AED deployment result-
ing in historically high survival rates provides opti-
mism that after decades of frustration, strategic
deployment of AEDs may offer an opportunity for
reducing out of hospital cardiac arrest mortality
rates. Our cost–utility model reported a base case
ﬁnding of $34,000 per QALY gained supports the
ﬁndings of Groeneveld et al. [26] that airline AED
deployment may be justiﬁed on both clinical and
economic grounds. If passive beneﬁt is factored into
the model, the cost-effectiveness of AED deploy-
ment improves even further.
To the best of our knowledge, nobody has
attempted to quantify passive beneﬁt or included it
in a cost–utility model. However, there is empirical
evidence that such a beneﬁt does exist. The FAA, as
part of its legislative process, collected public testi-
mony during 1998 to 1999 to measure public inter-
est in airline AED deployment (http://dms.dot.gov/).
Among many letters that were submitted, one eld-
erly individual wrote, “seniors who are concerned
are reluctant to ﬂy. If they are made aware of in-
ﬂight emergency medical care that is available, then
they may tend to move about the country more fre-
quently [36].” Similarly, airline industry executives
appear to recognize the importance of passive ben-
eﬁt. An article in Northwest Airlines WorldTraveler
magazine promoting the company’s AED deploy-
ment began, “What Happens if I get Sick During
My Flight [37]?” These two examples tell little
about the number of patients who may receive this
passive beneﬁt or the quantity of passive beneﬁt
they may receive. However, they do support our
contention that passive beneﬁt does exist.
Looking beyond airline AED programs, the con-
cept of passive beneﬁt may help to explain other
seemingly irrational health-related expenditures.
For example, several recent reports have detailed
the seemingly irrational behavior of spraying nox-
ious pesticides to kill mosquitoes and limit the
spread of West Nile virus. Spending millions of dol-
lars to spray potentially toxic chemicals on densely
populated areas in what has, to date, been an unsuc-
cessful attempt to limit the spread of the virus will
never make clinical and economic sense in a tradi-
tional cost–utility model. However, if the passive
beneﬁt that residents receive from the spraying is
accounted for, this behavior may appear to be more
rational. Passive beneﬁt may also help to explain
why the public supports other potentially irrational
expenditures including airport security screening or
heroic rescues of trapped coal miners.
Our cost-effectiveness model conﬁrms the results
of Groeneveld et al. [26] that airline AED deploy-
ment can be justiﬁed on clinical and economic
grounds. The results also suggest that the passive
beneﬁt from AED availability to the vast majority of
airline passengers who do not experience cardiac
arrests may be substantial. Passive beneﬁt should be
more precisely quantiﬁed to conﬁrm its existence
and magnitude. If passive beneﬁt can be shown to
exist, future cost–utility analyses that profess a
societal perspective should include this important
beneﬁt.
Figure 2  Sensitivity analysis of the effect of increasing the probabil-
ity of medical events on the incremental cost-effectiveness of airline
AEDs. By increasing the probability of medical events across the pub-
lished range (.0003-.0013 events per ﬂight), the expected number of
VF/VT arrests increases as well as shown in the ﬁgure. In the base
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Figure 3  Sensitivity analysis of the effect of increasing passenger
utility gained from passive beneﬁt on the incremental cost-
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